Johan Maertens frequently studies issues relating to Prospective cohort study and Internal medicine. Borrowing concepts from Microbiology, Johan Maertens weaves in ideas under Immunology. Borrowing concepts from Immunology, he weaves in ideas under Microbiology. Johan Maertens performs multidisciplinary studies into Gastroenterology and Hematology in his work. His Galactomannan research extends to the thematically linked field of Aspergillosis. Galactomannan and Aspergillosis are frequently intertwined in his study. Many of his studies involve connections with topics such as Hematopoietic stem cell transplantation and Transplantation. His work in Hematopoietic stem cell transplantation is not limited to one particular discipline; it also encompasses Transplantation. He undertakes multidisciplinary studies into Surgery and Oncology in his work.
Johan Maertens conducted interdisciplinary study in his works that combined Internal medicine and Intensive care medicine. His work often combines Immunology and Microbiology studies. While working on this project, Johan Maertens studies both Microbiology and Immunology. His research brings together the fields of Hematopoietic stem cell transplantation and Transplantation. He frequently studies issues relating to Transplantation and Hematopoietic stem cell transplantation. His multidisciplinary approach integrates Gastroenterology and Oncology in his work. Johan Maertens integrates many fields in his works, including Oncology and Gastroenterology. While working on this project, he studies both Surgery and Chemotherapy. He performs multidisciplinary study in the fields of Chemotherapy and Surgery via his papers.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
Oliver A. Cornely;Johan Maertens;Drew J. Winston;John Perfect.
The New England Journal of Medicine (2007)
Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial.
Stefan Janssens;Christophe Dubois;Jan Bogaert;Koen Theunissen.
The Lancet (2006)
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
Thomas J Walsh;Hedy Teppler;Gerald R Donowitz;Johan A Maertens.
The New England Journal of Medicine (2004)
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
J. Peter Donnelly;Sharon C. Chen;Carol A. Kauffman;William J. Steinbach.
Clinical Infectious Diseases (2020)
High-dose daunorubicin in older patients with acute myeloid leukemia.
Bob Löwenberg;Gert J. Ossenkoppele;Wim van Putten;Harry C. Schouten.
The New England Journal of Medicine (2009)
Galactomannan and Computed Tomography–Based Preemptive Antifungal Therapy in Neutropenic Patients at High Risk for Invasive Fungal Infection: A Prospective Feasibility Study
Johan Maertens;Koen Theunissen;Gregor Verhoef;Johnny Verschakelen.
Clinical Infectious Diseases (2005)
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial
Jürgen Finke;Wolfgang A Bethge;Claudia Schmoor;Hellmut D Ottinger.
Lancet Oncology (2009)
Efficacy and Safety of Caspofungin for Treatment of Invasive Aspergillosis in Patients Refractory to or Intolerant of Conventional Antifungal Therapy
Johan Maertens;Issam Raad;George Petrikkos;Marc Boogaerts.
Clinical Infectious Diseases (2004)
Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High–Loading Dose Regimen with Standard Dosing (AmBiLoad Trial)
Oliver A. Cornely;Johan Maertens;Mark Bresnik;Ramin Ebrahimi.
Clinical Infectious Diseases (2007)
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
Francisco M Marty;Per Ljungman;Roy F Chemaly;Johan Maertens.
The New England Journal of Medicine (2017)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: